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Abstract
Aims: Impairment in adenosine monophosphate-activated protein kinase (AMPK) activity and NOD-like re-
ceptor family, pyrin domain containing 3 (NLRP3) inflammasome activation are associated with several
metabolic and inflammatory diseases. In this study, we investigated the role of AMPK/NLRP3 inflammasome
axis in the molecular mechanism underlying pain perception. Results: Impairment in AMPK activation induced
by compound C or sunitinib, two AMPK inhibitors, provoked hyperalgesia in mice ( p < 0.001) associated with
marked NLRP3 inflammasome protein activation and increased serum levels of interleukin-1b (IL-1b)
(24.56– 0.82 pg/ml) and IL-18 (23.83– 1.882 pg/ml) compared with vehicle groups (IL-1b: 8.15– 0.44; IL-18:
4.92– 0.4). This effect was rescued by increasing AMPK phosphorylation via metformin treatment ( p< 0.001),
caloric restriction diet ( p < 0.001), or NLRP3 inflammasome genetic inactivation using NLRP3 knockout
(nlrp3-/- ) mice ( p < 0.001). Deficient AMPK activation and overactivation of NLRP3 inflammasome axis were
also observed in blood cells from patients with fibromyalgia (FM), a prevalent human chronic pain disease. In
addition, metformin treatment (200mg/daily), which increased AMPK activation, restored all biochemical
alterations examined by us in blood cells and significantly improved clinical symptoms, such as, pain, fatigue,
depression, disturbed sleep, and tender points, in patients with FM. Innovation and Conclusions: These data
suggest that AMPK/NLRP3 inflammasome axis participates in chronic pain and that NLRP3 inflammasome
inhibition by AMPK modulation may be a novel therapeutic target to fight against chronic pain and inflam-
matory diseases as FM. Antioxid. Redox Signal. 24, 157–170.
Introduction
Chronic pain is a multifaceted and highly variable con-dition with a high prevalence in the general population
worldwide. Several mitochondrial functions and inflammation
have been implicated in pain (11). Adenosinemonophosphate-
activated protein kinase (AMPK) has been shown to be in-
volved in the control of peripheral sensitization of nocicep-
tors and inflammatory nociception. Based on this evidence,
manipulations that provoke AMPK activation may be a novel
effective treatment for acute and chronic pain states (12, 25,
29). The AMPK cascade is one of the systems that have
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evolved to ensure that energy homeostasis is maintained even
under pathological conditions or stress (10). Recent findings
have implicated AMPK as an important contributor in NOD-
like receptor family, pyrin domain containing 3 (NLRP3)-
dependent inflammation and immunity (22, 28). The NLRP3
inflammasome complex is a molecular platform, which ac-
tivates innate immune defenses through the maturation of
proinflammatory cytokines (interleukins IL-1b and IL-18)
that are activated by a wide variety of danger signals (2, 26).
NLRP3 inflammasome has been related with some pain
conditions, such as neuropathic pain, fibromyalgia (FM), and
complex regional pain syndrome (6, 16, 15). Since AMPK
and the NLRP3 inflammasome pathway have been related
with nociception, we propose that AMPK downregulation
could be associated with pain symptoms through NLRP3
inflammasome activation. Our hypothesis also suggests that
both AMPK and NLRP3 inflammasome might serve as novel
therapeutic targets in the fight against hyperalgesia and
allodynia.
Results
To establish the causal role of AMPK in nociception, we
first performed a subchronic administration of compound C,
an AMPK inhibitor (20mg/kg/day), in mice. After 5 days of
administration, we evaluated the phosphorylation status of
AMPK as well as inflammasome activation in blood mono-
nuclear cells (BMCs) from vehicle and compound C-treated
mice. Compound C administration in mice inhibited AMPK
phosphorylation and induced inflammasome activation, as
FIG. 1. Inflammasome activation induced by AMPK inhibition in mice and effect of metformin treatment. N = 10
per group. (A) Protein levels of phosphorylated and nonphosphorylated AMPK (anti-AMPK and anti-pAMPK; Cell Signaling)
and NLRP3 (anti-NLRP3; Adipogen) from vehicle- and compound C-treated mice compared with GADPH protein in BMCs.
*p< 0.001, **p< 0.05 between vehicle and compound C-treated mice; ap< 0.001 and aap< 0.001 between compound C-treated
mice and metformin. (B, C) IL-1b and IL-18 in serum levels from mice treated with the vehicle or compound C and the
reduction after metformin treatment. *p< 0.001 between vehicle and compound C-treated mice; ap< 0.001 between compound
C-treated mice and metformin. (D) Pain sensitivity in vehicle- and compound C-treated mice was evaluated in the hot plate test
at 50–52.5 and 55C– 0.5C. *p< 0.05. (E, F) Evolution of pain sensitivity in vehicle- and compound C-treated mice treated
with metformin evaluated in the hot plate test at 50C and 55C. Data are shown as change of withdrawal latency with respect
to the control group. Negative and positive values represent hyperalgesia and analgesia, respectively.*p< 0.001 between
vehicle and compound C-treated wild-type mice. AMPK, adenosine monophosphate-activated protein kinase; BMCs, blood
mononuclear cells; IL-1b, interleukin-1b; NLRP3: NOD-like receptor family, pyrin domain containing 3. To see this illus-
tration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
Innovation
In recent years, inflammasome and AMPK have at-
tracted increasing interest among basic and clinical re-
searchers. Its implication in the pathophysiology of
several diseases generates new therapeutic strategies. Our
study shows an interesting role of AMPK/NLRP3-
inflammasome axis in chronic pain and that AMPK mod-
ulation can induce aNLRP3-inflammasome inhibitionwhich
could be a novel therapeutic target to fight against chronic
pain and inflammatory diseases such as FM.
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indicated by upregulation expression of NRLP3 protein in
BMCs, and increased serum levels of IL-1b and IL-18 (Fig.
1A–C). To verify the effect of AMPK inactivation on in-
flammasome modulation, we then examined the effect of
compound C in THP1 cells, which represent the most com-
monly used model cell line to study inflammasome activa-
tion, and the effect of compound C in skin fibroblasts from
AMPK knockout mice. Compound C induced activation of
inflammasome in THP1 cells, as indicated by increasing
expression levels of IL-1b (p17) (Supplementary Fig. S1;
Supplementary Data are available online at www.liebertpub
.com/ars), which was not observed in AMPK knockout fi-
broblasts (Supplementary Fig. S2). Moreover, compound C
administration produced a marked thermal nociception in
mice in the hot plate test when thermal stimuli were above
50C (latencies for compound C-treated mice were
7.36 – 1.06 [t (40)= 5.77; p< 0.001], 6.04 – 0.54 [t (8)= 5.7;
p < 0.001], and 3.96 – 0.31 [t (33)= 7.87; p < 0.001] seconds
faster than vehicle-injected mice at 50C, 52.5C, and 55C,
respectively; Fig. 1D). Interestingly, cotreatment with met-
formin (100 ng/kg/day), a potent AMPK stimulator (27),
during a period of 6 days induced partial AMPK activation
(AMPK phosphorylation) and reverted the effects of com-
pound C to values found in vehicle-injected mice, both at the
biochemical level (Fig. 1A–C) and thermal nociceptive be-
havior (Fig. 1E, F). Metformin treatment that induced partial
AMPK activation (Fig. 2A) significantly attenuated the de-
creased adenosine triphosphate (ATP) levels, reduced mito-
chondrial mass (citrate synthase activity), and increased
levels of lipid peroxidation in BMCs from mice treated with
compound C (Fig. 2B–D).
Then, to examine the role of NLRP3 inflammasome in
compound C-induced hyperalgesia, we compared the re-
sponse to AMPK inhibition between wild-type mice andmice
lacking NLRP3 (nlrp3-/- mice). Knockout mice of NLRP3
were not affected by compound C treatment, despite the in-
hibition of phosphorylated AMPK (Fig. 3A). In fact, NLRP3
mutant mice did not show thermal algesia changes after
compound C treatment compared with mutant mice treated
with vehicle (Fig. 3B, C). In addition, wild-type mice treated
with 16673-34-0 (5-chloro-2-methoxy-N-[2-(4-sulfamoyl-
phenyl)ethyl] benzamide) (Fig. 3D), a new specific inhibitor
of NLRP3 (18), reproduced nociceptive behavior found in the
nlrp3 ko mice. In addition, compound C-dependent increase
in IL-1b in wild-type mice was completely inhibited in the
NLRP3 ko mice (Fig. 3E).
Caloric restriction (CR) has previously shown to have
analgesic and anti-inflammatory effects in mice (7, 8). It has
been speculated that AMPK might mediate the beneficial
effects of CR (30). To assess the role of AMPK and in-
flammasome activation in pain modulation by CR, mice were
subjected to CR and ad libitum (AL) diets and pain assays
were performed. Mice subjected to CR diet during a period of
1 month developed a marked analgesia when compared with
AL-fed mice (Fig. 4A). Then, AL- and CR-fed mice were
injected with sunitinib (20mg/kg/day, i.p.), an efficient and
selective inhibitor of AMPK (13). The analgesic effect in-
duced by CR was reverted to control algesia levels in AL
mice after 7 days of treatment with sunitinib (Fig. 4A). In
addition, no changes in body weight were observed after
sunitinib treatment (Fig. 4B). Protein analysis in BMCs
confirmed that CR increased phosphorylated AMPK levels
FIG. 2. pAMPK phosphorylation levels, ATP, mitochon-
drialmass (citrate synthase), and lipidperoxidation inBMCs
from mice treated with vehicle or compound C for 10 days
(n58 per group). (A) pAMPK phosphorylation levels, (B)
ATP, (C) mitochondrial mass (citrate synthase), and (D) lipid
peroxidation in BMCs from mice treated with vehicle or com-
pound C for 10 days (n58 per group). All parameters were re-
stored after metformin treatment. Data represent the mean–SD
of three separate experiments. *p<0.001; **p< 0.01 between
control and compound C; ap< 0.001 between compound C and
metformin. ATP, adenosine triphosphate.
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compared with the AL group, but did not induce either
NLRP3 inflammasome activation or IL-1b protein matura-
tion (Fig. 4C), and increased serum IL-1b levels (Fig. 4D).
All beneficial effects observed by us in CR mice were re-
verted after a week of sunitinib treatment (Fig. 4A–C). Su-
nitinib is more potent than compound C, the commonly used
chemical inhibitor of AMPK (IC50 ranging between 45
and 62 nM for sunitinib vs. 1.3 and 2.4 lM for compound C)
(13). So, the repetition of the experiment of CR showed a
more significant effect of sunitinib than compound C (Fig.
4E, F) and supported the analgesic effect of CR by AMPK
modulation.
FIG. 3. AMPK inhibition in NLRP3 inflammasome-depleted mice. N = 10 per group. (A) Protein levels of phos-
phorylated AMPK in BMCs from vehicle- and compound C-treated wt and Nlrp3(-/-) mice. ap < 0.001 between wt and
Nlrp3(-/-) mice.*p < 0.001 between vehicle and compound C-treated wild-type mice. Western blot image was quantified
using ImageJ software (http://rsb.info.nih.gov/ij/download.html). (B, C) Depletion of NLRP3 in mice induced reduced
levels of pain in Nlrp3(-/-) mice compared with wild-type mice after compound C treatment. ***p< 0.001 between control
and control treated with compound C in the hot plate test at 50C and 52C, respectively. (D) Pharmacological inhibition of
NLRP3 by 166673-34-0 in mice induced reduced levels of pain after compound C-treated mice compared with saline and
compound C. Data are shown as change of withdrawal latency with respect to the control group. Negative and positive
values represent hyperalgesia and analgesia, respectively. (E) IL-1b in serum levels from wild-type and Nlrp3(-/-) mice
treated with the vehicle or compound C. *p < 0.001 between vehicle and compound C-treated wild-type mice. #p< 0.001
between Nlrp3(-/-) mice and wild-type mice.
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Next, we studied the relevance of the AMPK/NLRP3
inflammasome axis in FM, a prevalent human pain dis-
ease (Table 1). We found reduced levels of phosphory-
lated AMPK (Fig. 5A, B), decreased ATP levels (Fig.
5C), and increased mitochondrial reactive oxygen species
(ROS) in BMCs (Fig. 5D), as well as high levels of IL-
1b and IL-18 (Fig. 5E, F) in serum from patients with
FM. Interestingly, all these biochemical alterations were
restored to control values when BMCs from patients with
FM were treated with metformin. Since mitochondrial
FIG. 4. AMPK and NLRP3 inflammasome modulation by CR. N= 10 per group. (A) Evolution of pain sensitivity in AL
and CR mice treated with sunitinib evaluated in the hot plate test at 55C. Sunitinib treatment started after 1 month of AL and
CR. Data are shown as change of withdrawal latency with respect to the control group. Negative and positive values represent
hyperalgesia and analgesia, respectively. (B) Evolution of weight in AL and CR mice treated with sunitinib. (C) Protein levels
of phosphorylated AMPK, NLRP3, and matured IL-1b (p17) from sunitinib-treated mice after 15 days of treatment. (D) IL-1b
in serum levels from mice treated with sunitinib after 15 days of treatment in AL or CR conditions. *p< 0.001 between vehicle
and sunitinib-treated mice. (E) Evolution of pain sensitivity in AL and CR mice treated with compound C evaluated in the hot
plate test at 55C. (F) IL-1b in serum levels from mice treated with compound C after 15 days of treatment in AL or CR
conditions. *p< 0.001 between vehicle and compound C-treated mice. AL, ad libitum; CR, caloric restriction.
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dysfunction has been previously reported in BMCs,
platelets, and muscle from patients with FM (3, 5, 9), we
then decided to confirm these biochemical alterations in
fibroblasts derived from patients with FM. As in BMCs,
FM fibroblasts displayed a significant reduction of ATP
levels (Fig. 6A) associated with reduced expression lev-
els of active phosphorylated AMPK and tumor suppres-
sor kinase (LKB1), an activator of AMPK (Fig. 6B, C).
As mitochondrial ROS have been described to activate
AMPK, which subsequently induces a PGC-1a-dependent
increase of antioxidant defense, mainly MnSOD and
catalase (4), and NLRP3 inflammasome activation (27,
31), we next explored the expression levels of proteins
involved in these pathways. We found that reduced
AMPK activation was associated with low expression
levels of PGC-1a, TFAM, NRF1 and, interestingly, of
both MnSOD and catalase in FM fibroblasts (Fig. 6B, C).
In addition, mitochondrial superoxide production was
significantly increased in FM fibroblasts compared with
controls ( p < 0.001) (Fig. 6D).
The upregulation of antioxidant enzymes by AMPK
activation has been described as a defensive mechanism to
protect cells against oxidative damage. However, high
levels of oxidative stress and low levels of antioxidant
enzymes have been reported in FM (1, 5). Our results
suggest that AMPK inactivation or insensibility that im-
pairs antioxidant defense response could be involved in the
pathological mechanisms leading to high oxidative stress
in FM.
As our results suggested that AMPK and NLRP3 in-
flammasome may be involved in the molecular mechanism
underlying pain perception and activation of AMPK by
metformin or CR-modulated nociception in mice, we next
wondered if activation of AMPK had an analgesic effect on
FM patients. As a proof of concept, a small pilot trial was
designed: six women with FM (Table 2) received metformin
(200mg/daily), a reduced diabetic therapeutic dose. A sig-
nificant improvement in clinical symptoms was observed
after 1 month of metformin treatment. The clinical im-
provement was assessed by a reduction in the Fibromyalgia
Impact Questionnaire (FIQ) ( p< 0.001), with reduction in
pain, fatigue, morning tiredness, stiffness, anxiety, and de-
pression, all subscales of FIQ (Fig. 7A, B). Furthermore, we
observed a marked reduction in tender points ( p < 0.001),
pain visual scale ( p < 0.001), fatigue visual scale ( p < 0.01),
depression by Beck Depression Inventory (BDI) total score,
and sleep quality determined by the sleep visual scale and
Pittsburgh Sleep Quality Index (PSQI) ( p < 0.001) (Fig. 7C–
H). No adverse effects were observed during metformin
treatment. The clinical improvement induced by metformin
was associated with increased AMPK activation and reduced
NLRP3 expression levels in BMCs and decreased IL-1b and
IL-18 serum levels (Fig. 8A–C). Furthermore, a sustained
improvement in pain and other common FM symptoms was
observed in a long-term treatment with metformin after 7
months (Fig. 9A–G).
Discussion
Chronic pain is the most common symptom in FM. The
special characteristic of FM is pain perception in the ab-
sence of any damage. In this study, we show that AMPK
activation impairment may induce pain through the
NLRP3 inflammasome pathway. In mice models of pain,
an inverse correlation between pain sensation and AMPK
activation was also found. In contrast, increased AMPK
phosphorylation by pharmacological treatment with met-
formin or CR decreased the hyperalgesia induced by AMPK
dysregulation. Impairment of AMPK activation was associ-
ated with activation of the NLRP3 inflammasome pathway.
However, the causal relationship between nociception and
inflammasome is unknown. In this study, we demonstrated
that the levels of NLRP3 inflammasome were increased in
pain models where AMPK activation was reduced. These
data suggest that AMPK activation and NLRP3 inflamma-
some are central components in pain modulation. Never-
theless, the molecular mechanisms involved in the AMPK-
NLRP3 axis nociception regulation need further investiga-
tion. AMPK seems to work on nociceptors also at the sen-
sory neuron level in the spinal cord (23) through mTorc and
MAPK pathways, respectively, two kinases which play an
important role in pain plasticity. Additionally, it has been
reported that inflammasome is involved in periphery re-
sponse to acute inflammatory pain (17), although its role in
the central nervous system remains unknown. On the other
hand, mitochondrial dysfunction is a high defined alteration
in FM, which is not restored by the impairment of AMPK in
this study. In this sense, dysfunctional mitochondria are
selectively degraded by an autophagic process named mi-
tophagy and, interestingly, mitophagy has been shown to be
involved in FM in a previous study by our group (6). So, the
clearance of damaged ROS-producing mitochondria through
mitophagy is important for limiting excess NLRP3 signal-
ing (14). Accordingly, antioxidant treatment has shown to
inhibit NLRP3 stimulation (5, 14), and in the same sense,
autophagy induction should decrease NLRP3. Interestingly,
rapamycin, a known promoter of autophagy, has been
shown to inhibit IL-1b (23), so autophagy induction could
decrease pain perception.
Table 1. Anthropometric and Symptomatic
Parameters in Healthy Volunteers
and Patients with FM
Parameter Controls FM patients
Age (years) 45.5 – 6.1 46.1 – 8
Tender points — 14.5 – 1.8
Disease duration (years) — 8.1 – 3.3
Sex (male/female) 0/20 0/20
BMI (kg/m2) 23.2 – 2.5 22.9 – 1.2
FIQ total score, range 0–80 2.7 – 1.5 56.6 – 8.3a
Pain 0.6 – 0.2 6.9 – 2.1b
Fatigue 1.2 – 0.5 7.1 – 1.2a
Morning tiredness 1 – 0.3 5.5 – 1b
Stiffness 0.4 – 0.1 6.2 – 2.2b
Anxiety 1 – 0.5 5.8 – 1.2b
Depression 0.2 – 0.6 5.6 – 1.2a
VAS pain total score 0–10 0.7 – 0.2 7.5 – 2.1a
n = 20 and 30 for control and fibromyalgia groups, respectively.
ap< 0.001.
bp< 0.01.
BMI, body–mass index; FIQ, fibromyalgia impact questionnaire;
FM, fibromyalgia; VAS, visual analogue scale.
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Metformin is a known antidiabetic drug that upregulates
AMPK phosphorylation. Previous works (12, 21, 25, 27) and
our results here support the hypothesis that metformin can work
as an analgesic drug in rodent models of pain. In fact, these
studies suggest that AMPK activators can be an effective
treatment for human chronic pain diseases. Long-term treatment
with metformin mimics some of the benefits of CR through
AMPK activation and antioxidant protection by inducing a
decrease of both oxidative damage and inflammation (19). In
this regard, our results showed that patients with FM presenting
with low levels of phosphorylated AMPK and inflammasome
activation in BMCs, subjected to long-term treatment with
metformin, improved both pain and FM-associated symptoms.
As expected, AMPK and inflammasome activation levels were
restored to control values after metformin treatment. Our find-
ings reinforce the hypothesis that AMPK activators or NLRP3
inflammasome inhibitor may be a potentially effective therapy
in the fight against chronic pain.
However, we are aware of the limitations of our work.
Compound C is a cell-permeable pyrazolopyrimidine com-
pound that can act as a reversible and ATP-competitive in-
hibitor of AMPK, widely used in in vitro and in vivo assays to
study the role of AMPK. However, it has been shown that
compound C could have other effects. Recently, sunitinib, a
tyrosine kinase inhibitor (TKI) that binds to at least eight
receptor tyrosine kinases, has been shown to be a more ef-
fective inhibitor of AMPK (13). Therefore, we used both
compounds to study the role of AMPK from different per-
spectives. Of course, a better approach will be to carry out the
study in AMPK knockout mice. Furthermore, to avoid the
variability due to the estral cycle in female mice, only male
mice were used in this study.Working with rodents in general
is a factor that could restrict extrapolating these results to
humans, which is an evident limitation.
Furthermore, despite the fact that we explored the feasi-
bility of our hypothesis through a pilot trial with six patients
FIG. 5. Mitochondrial bioenergetic inflammasome and AMPK activation pathway in BMCs from patients with FM
and the effect of metformin. (A) Protein expression levels of phosphorylated AMPK determined in control and FM BMCs
from seven patients. (B) Protein levels were determined by densitometric analysis (IOD, integrated optical density) of three
different Western blots and normalized to total AMPK signal, using BMCs from patients with FM, compared with a pool of
five healthy age- and sex-matched control subjects. (C) ATP levels in control and FM BMCs with metformin. (D) Effect of
metformin in mitochondrial ROS production analyzed in BMCs from control and patients with FM. (E, F) IL-1b and IL-18
levels in the culture media of BMCs from FM patients incubated with metformin for 24 h and analyzed by ELISA. Data
represent the mean–SD of three separate experiments. *p< 0.001 between control and FM patients cells. ap< 0.001 between
patients with FM cells with and without metformin. FM, fibromyalgia; ROS, reactive oxygen species.
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with FM, further analysis involving more patients in double-
blind placebo-controlled clinical trials is required to confirm
these observations. Indeed, our research group is currently
working in this direction on the basis of the conclusions
discussed in this study.
Materials and Methods
Ethics statement
Approval by the ethics committee of the University of
Seville was obtained according to the principles of the
FIG. 6. Mitochondrial bioenergetic and AMPK activation pathway in fibroblasts from patients with FM. (A) ATP
levels in control and FM fibroblasts. Data represent the mean – SD of three separate experiments. *p< 0.001; **p < 0.01
between control and patients with FM. (B) Protein expression levels of antioxidants (MnSOD and catalase), mitochondrial
biogenesis, and phosphorylated and nonphosphorylated AMPK determined in control and FM fibroblast cultures. (C)
Protein levels were determined by densitometric analysis (IOD, integrated optical density) of three different Western blots
and normalized to GADPH signal, using fibroblasts from patients with FM, compared with healthy age- and sex-matched
control subjects. (D)Mitochondrial ROS production was analyzed in fibroblasts from control and three patients with FM by
flow cytometry as described in the Materials and Methods section. Data represent the mean – SD of three separate ex-
periments.*p< 0.001, ap< 0.01 between control and patients with FM.
Table 2. Anthropometric, Body Composition, and Biochemical Parameters in Patients
with FM Pre- and Post-Treatment with Metformin
Parameter Pretreatment (N= 6) Post-treatment (N= 6) Control (N = 10)
Age (years) 49.1 – 9 — 44.3 – 9.7
Duration of diseases (years) 6.9 – 3.3 6.6 – 3 7.1 – 3.8
Systol BP (mmHg) 134.2 – 19.4 136.4– 23.5 126.5 – 21.7
Diastol BP (mmHg) 76.9 – 9.6 78– 13.7 80.5 – 12.5
Pulse rate (bpm) 74.2 – 10.3 69– 6.8 78.8 – 14.5
Weight (kg) 70.5 – 11.2 73.2 – 13.8 67.8 – 13.7
BMI (kg/m2) 27.6 – 4 27.3 – 4.8 26 – 4.8
Body fat (%) 36.6 – 6.1 41.4 – 6 38 – 6
Muscle mass 42– 4.6 40.1 – 4.8 39.5 – 4.7
Bone mass 2.2 – 0.2 2.1 – 0.2 2.1 – 0.2
Visceral fat rating 7.9 – 2.6 10– 2.4 7.1 – 2.5
Metabolic age 53.9 – 13.6 60.4 – 0.5 47.1 – 1.2
Values are mean – SD.
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FIG. 7. Metformin improves clinical symptoms in patients with FM after 1 month of treatment. n= 6 patients were
treated with metformin. Clinical response of the patients after treatment by FIQ total score punctuation (A), several subitems
from the FIQ as pain, fatigue, morning tiredness, stiffness, and depression (B), tender points (C), VAS about pain (D),
fatigue (E), BDI (F), PSQI (G), and VAS sleep quality (H). Data represent the mean – SD.*p < 0.001 between before and
after metformin treatment in patients with FM. **p< 0.01 between before and after metformin treatment in patients with
FM. ***p < 0.05 between before and after metformin treatment in patients with FM. BDI, Beck Depression Inventory; FIQ,
Fibromyalgia Impact Questionnaire; PSQI, Pittsburgh Sleep Quality Index; VAS, visual analogue scale.
FIG. 8. Biochemical improvement
in FM patients after 1 month of
treatment with metformin. (A, B)
IL-1b and IL-18 levels in serum from
patients after metformin treatment. (C)
Protein expression levels of pAMPK
and NLRP3 in BMCs from patients
after oral treatment. Data represent the
mean–SD. #p< 0.001 between control
and before metformin treatment in
patients with FM. *p< 0.001 between
before and after metformin treatment
in patients with FM.
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Declaration of Helsinki and all the International Conferences
on Harmonization and Good Clinical Practice Guidelines. All
the participants of the study gave their written informed
consent before initiating it.
Pain studies in mice were performed in accordance with
the European Union guidelines (86/609/EU) and Spanish
regulations for the use of laboratory animals in chronic
experiments (BOE 67/8509-12, 1988). All experiments
were approved by the local institutional animal care
committee.
Patients
Briefly, 20 patients from the register of the Andalusian
Federation of Fibromyalgia (ALBA ANDALUCI´A) and 20
healthy matched controls were enrolled in the study, having
FIG. 9. Metformin long-term treatment after 7 months. (A) FIQ total score punctuation, (B) tender points, (C) VAS
about pain, (D) fatigue, (E) PSQI, (F) VAS sleep quality, (G) BDI.
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previously obtained informed consent and the approval of the
local ethics committee. The inclusion criterion was FM, based
on current American College of Rheumatology (ACR) diag-
nostic criteria, diagnosed 2–3 years ago. The clinical charac-
teristics of each group are shown in Table 1. Exclusion criteria
were acute infectious disease within the previous 3 weeks; past
or present neurological, psychiatric, metabolic, autoimmune,
allergy-related, dermal, or chronic inflammatory disease; un-
desired habits (e.g., smoking, alcohol consumption); medical
conditions that required glucocorticoid treatment, analgesics,
or antidepressant drugs; past or current substance abuse or
dependence; and pregnancy or current breastfeeding. Twenty
healthy women volunteers were included in the study and
matched with the recruited female patients with FM for age
range, gender, ethnicity, and demographic features (com-
pletion of at least 9 years of education and member of the
middle socioeconomic class). Healthy controls had no signs or
symptoms of FM and had not taken any medication for at least
3 weeks before commencing the study. None of the patients or
controls had taken any drug or vitamin/nutritional supplements
during the 3 weeks before blood sample collection. All patients
and controls followed a standard balanced diet (carbohydrate
50%–60%, protein 10%–20%, and fat 20%–30%) for 3 weeks
before blood collection, as established by a diet program.
Clinical data were obtained by physical examination and the
subjects were evaluated using the FIQ (total score ranged from
0 to 100, with higher scores indicating more severe symp-
toms), visual analogue scale (VAS) for pain, fatigue, and sleep
quality (range, 0–10, with higher scores indicating greater
symptom), BDI (range, 0–63, with higher scores indicating
greater symptom), and PSQI (range, 0–21, with higher scores
indicating worse sleep quality). Tender points were identified
by digital pressure at the 18 locations recommended by ACR,
which included a minimum of 11 of 18. Heparinized and co-
agulated blood samples were collected from patients and
controls after 12 h of fasting, centrifuged at 3800· g for 5min,
and the plasma and serum were stored at -80C until testing.
Serum biochemical parameters were assayed by routine ana-
lytical methods. A routine laboratory test yielded normal
results for glucose, uric acid, creatine kinase, aspartate ami-
notransferase, alanine aminotransferase, cholesterol, and tri-
glycerides (data not shown).
Reagents
Trypsin and metformin (in vitro assay) were purchased from
Sigma Chemical Co. MitoSOX was purchased from In-
vitrogen/Molecular Probes. Anti-GAPDH monoclonal anti-
body, clone 6C5, was purchased from Research Diagnostic,
Inc. Anti-NLRP3 antibody was purchased from Adipogen.
Anti-PGC-1a and OGG-1 antibodies were from Abcam; anti-
AMPK and anti-p-AMPK antibodies were fromCell Signaling;
and anti-coq antibodies and TFAM, NRF1, MnSOD, and cat-
alase antibodies were purchased from Santa Cruz Biotechnol-
ogy. A cocktail of protease inhibitors (complete cocktail) was
purchased from Boehringer Mannheim. The Immun-Star HRP
substrate kit was from Bio-Rad Laboratories, Inc.
Cell cultures
Peripheral BMCs were purified from heparinized blood by
isopycnic centrifugation using Histopaque-1119 and Histo-
paque-1077 (Sigma Chemical Co.). BMCs were cultured
at 37C in a 5% CO2 atmosphere in RPMI-1640 medium
supplemented with l-glutamine, an antibiotic/antimycotic
solution (Sigma Chemical Co.), and 10% fetal bovine serum
(FBS).
Murine fibroblasts were extracted from 12-week-old mice
ears. The ears were sterilized with ethanol, washed with
phosphate-buffered saline (PBS), and triturated with razor
blades. The resulting samples were incubated with 600ll of
4mg/ml collagenase D (Roche) and 4mg/ml of dispase II
(Roche) in Dulbecco’s modified Eagle’s medium (DMEM)
for 45min in 5% CO2 at 37C. After filtering and washing,
6ml of DMEMwith 10% FBS and 1% antibiotic–antimycotic
were added, and the mixture was incubated in 5% CO2 at
37C. Approximately 106 cells were passed in a 10-cm plate
every 3 days and cultured under standard conditions.
Treatment
Two millimolars of metformin (Sigma Aldrich) and/or
100lM of H2O2 at 48 h were used for in vitro experiments.
Western blotting
Whole cellular lysate from fibroblasts was prepared by
gentle shaking with a buffer containing 0.9% NaCl, 20mM
Tris–HCl, pH 7.6, 0.1% Triton X-100, 1mM phenylmethyl-
sulfonyl fluoride, and 0.01% leupeptine. Electrophoresis
was carried out in a 10%–15% acrylamide sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS/PAGE).
Proteins were transferred to Immobilon membranes (Amer-
sham Pharmacia). AMPK, AMPK-P, PGC-1a, NRF1,
TFAM, MnSOD, and catalase antibodies were used to detect
proteins by Western blotting. Proteins were electrophoresed,
transferred to nitrocellulose membranes, and, after blocking
overnight at 4C, incubated with the respective antibody
solution diluted at 1:1000. Membranes were then probed
with their respective secondary antibody (1:2500). Immuno-
labeled proteins were detected by using a chemiluminescence
method (Immun-Star HRP substrate kit; Bio-Rad Labora-
tories, Inc.). Protein was determined by the Bradford method.
Western blot image was quantified using ImageJ software
(http://rsb.info.nih.gov/ij/download.html).
IL-1b and IL-18 levels
IL-1b (GenWay) and IL-18 (Biosensis) levels in serum or
culture media were assayed in duplicates by commercial
ELISA kits.
ATP levels
ATP levels were determined by a bioluminescence assay
using an ATP determination kit from Invitrogen/Molecular
Probes according to the instructions of the manufacturer.
Mitochondrial ROS production
Mitochondrial ROS generation in BMCs and fibroblasts
were assessed by MitoSOX Red, a red mitochondrial super-
oxide indicator. MitoSOX Red is a novel fluorogenic dye re-
cently developed and validated for highly selective detection
of superoxide in the mitochondria of live cells. MitoSOX Red
reagent is live-cell permeant and is rapidly and selectively
targeted to the mitochondria. Once in the mitochondria,
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MitoSOX Red reagent is oxidized by superoxide and exhibits
red fluorescence. Approximately 1 · 106 cells were incubated
with 1 lM MitoSOX Red for 30min at 37C, washed twice
with PBS, resuspended in 500 ll of PBS, and analyzed by
flow cytometry in an Epics XL cytometer, Beckman Coultier,
Brea, CA (excitation at 510 nm and fluorescence detection at
580 nm).
Animals and drug administration
For all experiments, to avoid the variability due to the
estral cycle in female mice, only male mice were used in this
study. Nlrp3-/ - transgenic mice (C57BL/6 background),
provided by FG mice, have been previously described (20).
Ten-week-old male C57/BL6/J mice weighing 25–30 g were
maintained on a 12-h light/12-h dark cycle. Behavioral
studies were performed in accordance with the European
Union guidelines (86/609/EU) and Spanish regulations for
the use of laboratory animals in chronic experiments (BOE
67/8509-12, 1988). All experiments were approved by the
local institutional animal care committee. Compound C, a
specific inhibitor of AMPK, was dissolved in saline (vehicle)
and intraperitoneally administered at a dose of 20mg/kg/day
for 15 days. Sunitinib (BioVision), a more specific inhibitor
of AMPK, was dissolved in DMSO (vehicle) and intraperi-
toneally administered at a dose of 20mg/kg/day for 15 days
in 60 ll as total volume per day. 5-Chloro-2-methoxy-N-[2-
(4-sulfamoylphenyl)ethyl]benzamide (16673-34-0) (Sigma
Aldrich) was dissolved in DMSO (0.05–0.1ml). Mice were
treated with 100mg/kg/day for 15 days. Behavioral tests were
performed 5 days after the first drug administration. After
testing, mice were anesthetized with CO2 and sacrificed by
decapitation. Blood samples were collected for immediate
biochemical analysis and BMCs were isolated. Serum sam-
ples were frozen at -80C for further analyses.
Calorie restriction was a progressive process that was initi-
ated with 10% restriction during the first week, followed by
20% and 30% during the second and third weeks, respectively,
and maintained at 30% until the end of the treatment.
Behavioral assays
Behavioral analyses were performed in a testing roomwith
homogeneous noise and light levels. The testing apparatus
was cleaned with 70% ethanol (Panreac Quı´mica S.A.U.)
between trials to eliminate any influence of animal odor on
the exploratory behavior.
Pain assay
For the hot plate test, a glass cylinder (16 cm high, 16 cm in
diameter) was used to constrain the mice to the heated surface
of the plate. The plate surface was maintained at 50C–
55C – 0.5C and the latency to commence paw licking was
measured, with a cutoff of 30 s. Data are shown as change of
withdrawal latency compared with the control group. Nega-
tive and positive values represent hyperalgesia and analgesia,
respectively.
Metformin treatment in patients
Six volunteer patients who had not taken any drug or
vitamin/nutritional supplements were supplemented with
metformin (Merck & Co., Inc.) for 1 month (200mg/day in
the morning). After 1 month of treatment, heparinized blood
samples were collected after 12-h fasting and 24 h after the
last dose, and clinical symptoms were evaluated. All patients
had a sedentary lifestyle. All patients and controls followed
a standard balanced diet (carbohydrate 50%–60%, protein
15%–20%, and fat 25%–30%) for 3 weeks before blood
collection and during treatment with five meals per day to
avoid reduction in glucose, as established by a diet program
supervised by a clinical dietitian. Patient routine laboratory
tests yielded normal results (data not shown).
Outcome measurements
The primary outcome measurement was the change in the
FIQ score from baseline to the end of the intervention. The
FIQ is a well-validated multidimensional measurement of the
overall severity of FM as rated by patients. Categories in-
cluded the intensity of pain, physical functioning, fatigue,
morning tiredness, stiffness, depression, anxiety, job diffi-
culty, and overall well being. The total score ranged from 0 to
100, with higher scores indicating more severe symptoms.
Secondary efficacy measurements included reduction in the
number of positive tender points, a VAS (range, 0–10, with
higher scores indicating greater pain), and PSQI (range, 0–
21, with higher scores indicating worse sleep quality).
Body composition
Several parameters related to body composition (weight,
BMI, body fat, muscle mass, bone mass, visceral fat) were
determined using the TANITA BC-601 machine (TANITA,
Middlesex, United Kingdom).
Statistical analyses
Statistical analyses were performed using the SPSS package
for Windows (SPSS). Unless otherwise indicated, data repre-
sent the mean–SEM. The unpaired Student’s t-test was used
to evaluate the significance of differences between groups,
accepting p< 0.05 as the level of significance. Two-way
analysis of variance (ANOVA) was used to compare the be-
havioral results from animals treatedwith vehicle alone orwith
compound C. Chi-squared tests were used for statistical
analysis in cases inwhich qualitative variables were compared.
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BMCs¼ blood mononuclear cells
CR¼ caloric restriction
DMEM¼Dulbecco’s modified Eagle’s medium
FBS¼ fetal bovine serum
FIQ¼ Fibromyalgia Impact Questionnaire
FM¼ fibromyalgia
IL¼ interleukin
NLRP3¼NOD-like receptor family, pyrin domain
containing 3
PBS¼ phosphate-buffered saline
PSQI¼ Pittsburgh Sleep Quality Index
ROS¼ reactive oxygen species
VAS¼ visual analogue scale
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